P/E ratio

Equity and Bond Returns: The End of a Golden Era? Despite numerous periods of global financial excesses, and subsequent corrections, over the past 30 years, the returns on equities and bonds in the US and Europe have been considerably above their long-term (100 year) averages. The outperformance has been most pronounced in long-dated government bonds. The average annual real return on these instruments between 1985 and 2014 was +5.0% in the US and +5.9% in Europe, compared to long-run returns of

Equity and Bonds Returns: The End of a Golden Era? Despite numerous periods of global financial excesses, and subsequent corrections, over the past 30 years, the returns on equities and bonds in the US and Europe have been considerably above their long-term averages. The outperformance has been most pronounced in long-dated government bonds. The average annual real return on these instruments between 1985 and 2014 was +5.0% in the US and +5.9% in Europe, compared to long-run returns of +1.7% and

Walgreens Corporations Financial Analysis Introduction Walgreens operates 7,907 locations in 50 states, the District of Columbia, Guam and Puerto Rico with over 247,000 employees serving customers. The company has seen an increase in revenues, but an end to its contract to participate in the Express Scripts pharmacy provider network on December 31, 2011 poses a threat to revenues and profits for 2012 and future fiscal periods. This analysis will discuss Walgreen’s business strategy, provide a

through P/E ratio, P/B ratio, and Constant growth. Then, we first have to determine their growth rate using Fisher formula [(1+g)x(1+inflation)]-1. With population growth rate 1%, economic growth rate 3%, and pharmaceutical growth rate 5%, we can get nominal rate :population: [(1+0.01)x(1+0.02)]-1 = 3% economic: [(1+0.03)x(1+0.02)-1 = 5% pharmaceutical: [(1+0.05)x(1+0.02)]-1 = 7% our group chooses economic nominal rates 5% as input for constant growth estimation. I. PRICE EARNINGS RATIO   Arcadian

2011. Pfizer’s debt ratio has also been above the benchmark since 2009, but it has been lower than Lilly’s. Lilly’s long-term debt-to-equity ratio was over the benchmark during the year 2008 and 2009 but stayed below 1.0 in the other years. It should be noted that Lilly’s debt ratio has declined during the period, whereas, Pfizer’s increased. Although, Lilly’s long-term debt-to-equity ratio appears to be good, its total debt-to-equity ratio, which is much more comprehensive, is above the reasonable

stockholders. A) Liquidation value B) Book value C) The P/E multiple D) The present value of the common stock 8) ________ is the actual amount each common stockholder would expect to receive if the firm's assets are sold, creditors and preferred stockholders are repaid, and any remaining money is divided among the common stockholders. A) Liquidation value B) Book value C) The P/E multiple D) The present value of the dividends 9) ________

Corporate Finance (Berk/DeMarzo) Chapter 9 - Valuing Stocks 9.1 Stock Prices, Returns, and the Investment Horizon 1) Which of the following statements is false? A) There are two potential sources of cash flows from owning a stock. B) An investor will be willing to pay a price today for a share of stock up to the point that this transaction has a zero NPV. C) An investor might generate cash by choosing to sell the shares at some future date. D) Because the cash flows from stock are known with certainty

In the research, the next three years performance is estimated by different stage. Generally speaking, the first stage will be only the next year 2016, which is basic on the average historical performance. The second stage will be 2017 and 2018, the growth is assumed to keep about 9.6 % per year. In addition, all the figures in this part are calculated by Danish Kroner. Basic on the last five years’ income statement, sales in Novo Nordisk will increase from DKK 107927 million in 2015 to DKK 134004

………………………………………………………….11 5.1 Key Financial Ratios………………………………………………11-12 6.0 Valuations………..…………………………………………………………15 6.1 Dividend Valuation Model…………………………………………14-16 6.2 Price-Earnings(P/E) Model.………………………………………..17 7.0 Limitations……………………………………………………………………18 8.0 Conclusions and Recommendations……………………………………...19 5.0 List of References……………………………………………………………20-22 APPENDIX 1 Qantas Airways Ltd – Key Facts…….………………………………….23-24 2 Ratio

NIKE, INC VS TOYS R U Page LIST OF ILLUSTRATIONS…………………………………………………………….2 INTRODUCTION……………………………………………………………………….4      Procedures………………………………………………………………………..4            COMPANIES.........……………………………………………………………………...4 COMAPARISONS………………………………………………………………………7 GROWTH………………………………………………………………………………..9 CONCLUSION AND RECOMMENDATIONS………………………………………..11 REFERENCES…………………………………………………………………………..12